Deutsche Bank Maintains Sell on AstraZeneca (AZN) [Yahoo! Finance]
AstraZeneca PLC Ordinary Shares (AZN)
Last astrazeneca plc ordinary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
Deutsche Bank Maintains Sell on AstraZeneca (AZN) On March 27, 2026, Deutsche Bank maintained a Sell rating on AstraZeneca PLC (NYSE:AZN). The firm's analyst kept a price target of £115 on the stock. On the other hand, in a more recent update, Guggenheim raised the firm's price target on AstraZeneca PLC (NYSE:AZN) from 16,000 GBp to 16,500 GBp. Analyst Seamus Fernandez kept a Buy rating on the company's stock. The firm made the adjustment following an update of its financial model ahead of Q1 earnings. In another development, on March 31, 2026, AstraZeneca PLC (NYSE:AZN) announced positive Phase III results for efzimfotase alfa – an investigational enzyme replacement therapy for hypophosphatasia. The program covered 196 patients across 22 countries to provide a lower-volume, less frequent dosing alternative to Strensiq. The MULBERRY trial met all primary endpoints in treatment-naive pediatric patients, showing significant bone health improvements. In addition, the CHESTNUT study
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC Ordinary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp [Yahoo! Finance]Yahoo! Finance
- IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancerBusiness Wire
- Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPDBusiness Wire
- Astrazeneca (AZN) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AZN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "buy"MarketBeat
- Astrazeneca (AZN) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
AZN
Sec Filings
- 4/2/26 - Form 6-K
- 4/1/26 - Form 6-K
- 3/31/26 - Form 6-K
- AZN's page on the SEC website